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Abstract 
Objective To explore the users’ perspectives regarding the effects and toxicity of cathinones.  
Methods A systematic search of Internet discussion forums yielded 303 threads relevant to 
the research objectives. The threads were analysed by conventional content analysis where 
concepts were developed from codes and themes. 
Results The study identified three main themes in relation to cathinone use, effects and 
toxicity. The first theme considered the modalities of intake of cathinones in relation to the 
derivative taken (mainly mephedrone, 3-methylmethcathinone and 
methylenedioxypyrovalerone), route of administration (eyeballing, insufflation, smoking, 
intravenous, oral, rectal and sublingual), multi-drug use and purity of the cathinone 
derivative. The second theme characterised the main effects of cathinones i.e. increased 
energy, euphoria and empathogenic. Toxic effects were reported regarding the nervous 
system (anxiety, hallucinations, nervousness, paranoia), cardiovascular system (angina, 
myocardial infarction, tachycardia), skin (discolouration, itching, allergy) and renal system 
(difficulty in urination). Drug-drug interactions were also reported including multiple drug 
use between cathinones, stimulants, depressants and hallucinogens. 
Conclusions The Internet discussion forums provide useful sources of information regarding 
the effects and toxicity of cathinones which can be taken into account when assessing the 
safety of drugs. 
 
Keywords Novel psychoactive substances, cathinones, content analysis, effects, toxicity, 
users’ perspectives 
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Introduction 
Novel psychoactive substance (NPS) have emerged over the last decade as legal alternatives 
to classical drugs of abuse (Gibbons, 2012). Until 2015, the European Monitoring Centre for 
Drug and Drug Addiction (EMCDDA) identified more than 560 NPS derivatives (EMCDDA, 
2016). The Internet played a role in the spread of NPS through marketing, sales and 
distribution (ACMD, 2011; Corraza et al. 2014) therefore, monitoring the Internet is crucial 
in order to identify trends in the use amongst the NPS and their effects (Deluca et al., 2012). 
 
Synthetic cathinones are one of top reported groups of NPS in Europe (James et al. 2010; 
Tsujikawa et al., 2015; UNODC, 2014). Along with synthetic cannabinoids, synthetic 
cathinones represent two-thirds of the drug market (Cottencin et al., 2013).  In 2013 10,657 
seizures of synthetic cathinones were reported (EMCDDA, 2016). Amongst synthetic 
cathinones, mephedrone was the most widely used derivative (Dargan et al. 2011; Stevenson 
and Richardson, 2014). There is however limited information regarding the effects and 
toxicity of synthetic cathinones in the scientific literature. Most of the available information 
is limited to emergency department and/or users’ reports (Dargan, Albert and Wood, 2010). 
E-psychonauts are users who meet over Internet forums and discuss their experience with 
psychoactive drugs including NPS (Hohmann et al., 2014; Davey et al., 2012). The aim of 
this work is to determine the users’ perspectives regarding the effects and toxicity of 
cathinones. 
 
Methods 
Study design 
A qualitative study of Internet discussion forums was undertaken to explore the knowledge 
regarding the effects and toxicity associated with the use of cathinones.  
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Data collection 
Data was obtained from the Internet by searching for published threads regarding the 
experiences of synthetic cathinones between January and March 2015. Different 
combinations of keywords were used mainly in Google, and included: “cathinone(s)”, 
“report”, “experience”, “use”, “misuse”, “effects”, “adverse reactions”, “toxicity”. The first 
20 hits of each search were inspected carefully. After examination, the search yielded seven 
sites related to the use of cathinones (Table 1). These sites were further examined to explore 
the experiences described by cathinone-users. Inclusion criteria were threads that 
communicated a subjective experience of users regarding the use of cathinones. Exclusion 
criteria were: threads that discussed synthesis or prices of cathinones. Subsequently, 371 
discussion threads were recovered from the seven websites. The threads were then assessed 
in further details where 303 threads (of 2,854 posts) were found relevant to the objectives of 
the study (Table 1). When the thread was considered as relevant, all information relating to 
user names and complete URLs were deleted in order to protect the identity of authors. 
 
List of definitions 
An adverse drug reaction is defined as “ any noxious, undesired and unintended drug effect 
that occurs at doses used in human for therapy, diagnosis or prophylaxis” (WHO, 1972). A 
drug drug interactions is defined as “an action of a drug on the effectiveness or toxicity of 
another drug” (Vervloet and Durham, 1998). Eyeballing is defined as the direct pouring of 
the NPS solution on the ocular surface epithelium (Burillo-Putze et al., 2013). Smoking is 
done either using a joint or a pipe and could involve the intake of a single drug or a mixture. 
Intravenous intake involves the direct injection of the NPS solution into the vein. Nasal 
insufflation comprises the snorting of the NPS powder. Oral intake involves the swallowing 
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of the tablet and/or liquid (mixture of drug in alcohol or juice), or bombing. Bombing (or 
parachuting) encompasses wrapping the NPS (powder) in cigarette paper and swallowing it. 
Rectal (or plugging) administration encompasses injecting solution of the NPS via a needless 
syringe.  Sublingual intake involves placing the NPS powder under the tongue for less than 
five minutes or until the taste becomes unbearable. 
 
Analysis 
Qualitative data relating to the use of cathinones were analysed. The data included anything 
the participant reported in threads. The threads were subjected to conventional content 
analysis (Hsieh and Shannon, 2005). Data in threads were initially coded independently by 
two investigators (SA and NG) in order to minimise bias. The threads were read carefully 
line-by-line in order to identify codes and themes that reflected concepts. After the threads 
were coded, both investigators met in order to discuss any discrepancies among codes, cluster 
codes into themes and discuss potential relationships among themes that constituted 
categories. Three broad themes were achieved relating to the uses, pharmacological effects 
and toxicity described by users. The inter-rater reliability of the themes was evaluated by 
providing the threads to a third researcher (DO). Threads and codes were provided to the 
research without the themes. The inter-rater reliability for the final themes was 93% which 
indicated the validity of the coding methodology.  
 
Ethical considerations 
The study has been performed in accordance with the ethical standards as laid down in the 
1964 Declaration of Helsinki and its later amendments or comparable ethical standards. 
Ethical approval was sought from BU Internal ethics committee. The study involved 
collecting information that was already available in the public domain. However, anonymity 
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was applied to participant data. All participants’ data that could indicate identities/nicknames 
were removed from the threads, and each thread was give a number. No posts or contribution 
to the discussion forum were made and no data was shared outside the remits of the study. 
 
 
Results 
The analysis of the discussions relating to cathinones from Internet sources yielded 303 
threads with 2,854 posts. These were combined into three main themes: (1) uses, (2) 
pharmacological effects and (3) toxicity. 
 
Uses 
Three main subthemes emerged under uses: the route of administration, multidrug use and 
purity. 
 
Route of administration 
This subtheme uncovered information relating to the modality of intake of cathinones in 
relation to the: (1) derivative taken, (2) route of intake, (3) matrix, (4) frequency and (5) 
purity. A total of 27 cathinones were reported in the discussion threads and included alkyl- (n 
= 12), halogen- (n = 4), methlenedioxy- (n = 6) and pyrrolidinyl- (n = 5) substituted 
derivatives (Table 2). The main derivatives among these cathinones were methylone, 
mephedrone, 3-methylmethcathinone (3MMC) and methylenedioxypyrovalerone (MDPV), 
and were reported by 286, 240, 199 and 173 users respectively.  
 
Where reported, the intake of the aforementioned cathinones was deployed via single route of 
administration or combination of two routes of administration at a time. The majority of the 
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users (n = 220) reported the use of a single route of administration.  Single routes reported 
were: eyeballing (n = 2), smoking (n = 21), intravenous (n = 19), nasal insufflation (n = 90), 
oral by juicing or direct swallowing (n = 58), oral by bombing (n = 12), rectal (n = 13) and 
sublingual (n = 4). Nasal insufflation was the most popular route among the users (n = 90). 
The doses of cathinones insufflated varied massively between 2 mg to 1.5 g. Users had mixed 
feelings about nasal insufflation. Users in favour of nasal insufflation described it as ‘quick’, 
‘intense’, ‘works well’, ‘produced more love or empathy’, ‘very productive, active and 
focused’. Users who did not like nasal insufflation stated it was ‘highly addictive’, 
‘completely changes the drug effects to coke line’, ‘dirty high’, ‘produces nose aches’, ‘burns 
like hell’, ‘stung like hell’, ’waste of drug’, and the ‘longest lasting route’. One user reported 
regarding nasal insufflation: 
 
‘Mostly nasal route-despite the nasty sting, there’s something 
about sticking drugs up the nose that makes it more moreish and compulsive, fun even (I’m 
sure we all know that)’ (Thread, 114) 
 
 The second major route by users was direct swallowing of the cathinone derivative (n = 58). 
This was carried out either by swallowing the drug itself or by mixing it with a juice/energy 
drink. Dosage taken of cathinone varied between 10 mg and 2.5 g over different time 
intervals and frequencies. Intervals ranged between two hours (assumed as duration of action 
of cathinones) and up to four hours. The frequency also had wide differences between users 
from once a week once every six months. Users felt direct swallowing was slow, ineffective 
but safe. They stated that by direct swallowing they had ‘nothing noticed’, ‘zero effects’, ‘is 
usually fine’, ‘much more mellow’, ‘less speedy’ and ‘never had a problem’.  
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Smoking route was less popular among users (n = 20) due to the unwanted effects reported 
such as: ‘most insane panic/delirium attack’, ‘harsh’, ‘burns the throat’, ‘does not appear to 
get any heavier’, ‘lungs felt weird’, ‘disgusting smell’, ‘’high anxiety’ and with ‘little effect’. 
Only three users reported getting the desired effects using the smoking routes and described 
the effects as ‘melts right on vaping’, ‘stimulation’ and ‘rushing’. The dose of cathinones 
used for this route was only reported by five users who smoked 10 mg, 25 mg, 60 mg, 400 
mg and 500 mg.  
 
Though only 19 users reported the IV route, it was the preferred route of administration. 
Users enjoyed the IV route as it was ‘pretty intense’, ‘pretty godly’, ‘gave a noticeable rush’ 
and ‘induced immediate visual and auditory hallucinations’. Only three users reported the 
doses of cathinones taken by IV route which were 80-210 mg, 150 mg and 3-4 g. 
 
The rectal route was also popular among users (n = 13) and described as ‘quiet pleasant’, 
‘amazing’, of quick onset and long duration but dose-dependent. The ideal dose was specified 
by one of the users as 50-75 mg. Other reported doses were 140 mg, 150 mg, 500-600 mg 
and 10 g. 
 
Multi-drug use 
Cathinones were often taken in combination with other drugs (n =60) that included both 
classical drugs of abuse and NPS. The multi-drug abuse was either a binary or ternary 
mixtures. Classical drugs reported were stimulants (amphetamine derivatives, cannabis, 
cocaine, coffee, lidocaine and tobacco), depressants (alcohol, herbal sleep aids and 
benzodiazepines), hallucinogens (LSD, magic mushrooms and ketamine), vitamins and 
supplements and stimulant/depressant mixtures (mephedrone-cannabis-alcohol, mephedrone-
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cocaine-ketamine and mephedrone-cannabis-caffeine). NPS used in mixtures were mainly 
3FA, 3FMC, ethylphenidate, mephedrone, methylone, MDPV and MXE. 
 
Purity of cathinones 
The purity of cathinone products was reported from 40 threads and varied between 
derivatives. For all derivatives, indicators of purity were the effects of the NPS (gross, 
nausea, potent), smell (chemical odour, flowery aroma, pungent, root beer/liquorice odour, 
semen smell, sharp sour, speedy smell, sweet smell), taste (bitter, chalky, disgusting, slightly 
bitter, synthetic bitter, unpleasant), colour (beige, browny grey, pure bright white powder, 
snowwhite, urine-smell, white, yellow) and physical properties (big snowflakes, clumpy, 
crumbly, crystal rock batches, fine-powder, paste-like, sticky, wet clay). One user compared 
3-MMC to impure cocaine: 
 
“Methcathinone is a stimulant all right,  
But it feels like bad coke cut hard with speed”. 
 
Another user adopted colour as indicator and described alpha-PVP as impure despite its white 
colour: 
“…was the white one…but it definitely contains some impurities” 
 
 
Pharmacological effects 
Users sought effects that increased mood or mental performance when using cathinones. The 
main psychological effect (n = 53) reported by users was euphoria. Users took euphoria as a 
basis for choosing the cathinone derivative and reported effects relating to euphoria as: 
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blissfulness, body warmth, emotional, confidence, having happy thoughts, mood-lifting. The 
three derivatives 4MEC, MDPV and mephedrone were encountered as strong euphoric 
agents. 3MMC, alpha-PHP, alpha-PVP, ethcathinone and methylone were experienced as 
mild euphoric agents. 3MMC was described as the mildest of the cathinone derivatives: 
 
“3MMC is borderline intense roll...but still mellow just like MDMA.....let's put it this way....if 
I was given 3mmc and told it was MDMA, I would of believed it completely. You can't tell the 
difference, or at least I can't.” 
 
Effects of 3MMC were below expectations: 
 
“Pretty good rush, but real euphoria never seems to come.” 
 
Users were also interested in the empathogenic effects (n = 78) associated with cathinones, 
being: active listening, affectionate, appreciation for music, emotional intimacy, feeling 
drunk, feeling happy and grateful, and loving everyone:  
 
“Methylone…..found it my hold grail! I felt at peace with the world 
And loved everything all the way down to very small object!” 
 
Hence 16 users took cathinones as alternative to antidepressants and reported them as more 
effective than antidepressants. One user reported: 
 
“The antidepressant effects were immediate and I’ve woken up feeling  
like completely changed person. I’ve been on SSRIs and other meds for years... 
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I feel like the real me is finally back.” 
 
Stimulation and increased energy were also reported for (n = 50) where users felt alert and 
were able to stay awake and productive for longer hours (up to 34 hours). They were very 
attentive, smart, creative, highly motivated, organised and able complete their work on time. 
One user reported regarding MDPV: 
 
“While less giddy and chatty, I was still working like a freaking machine.” 
 
The aforementioned characteristics increased sociability among users who felt ‘talkative’, 
‘with a sense of self-satisfaction’, ‘low anxiety’ and ‘having intense conversations’. 
Nonetheless, the stimulation/alertness was high where five users reported an ‘overactive 
mind’ with ‘200-1000 thoughts per second’. Users (n = 37) also experienced increased sexual 
activity associated with the use of cathinones. They described mephedrone and MDPV as 
stronger aphrodisiac than 3MMC and methylone.  
 
Toxicity 
Adverse drug reactions 
Symptoms of ‘adverse drug reactions’ and drug-drug interactions were encountered among 
users. Adverse drug reactions were reported for nervous, cardiovascular, renal, skin and 
respiratory systems. The nervous system had the highest reports among users (n = 270) where 
cathinones were described as highly addictive with desire to re-dose, irritable on coming 
down, dehydrating and causing self-harm. Specific adverse effects associated with the use of 
cathinones were anxiety, nervousness, irritability, restlessness, headache, insomnia, paranoia, 
feeling of regret, disturbed sleep, bruxism, extreme mydriasis, cognitive impairment, 
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forgetfulness, lack of concentration, auditory hallucinations, disorientation, difficulty of 
speech, numbness of face and extremeties, sweating and involuntary body movement. 
Cardiovascular adverse effects were the second most reported (n = 246) and included: 
Angina, arrhythmia, cardiac arrest, damaged veins, heart attack, heartache, hypertension, 
myocardial infarction, palpitations, tachycardia and vasoconstriction. Often cardiovascular 
effects were seen dependent on the derivative, dose and duration of intake (acute versus 
chronic). Cardiovascular adverse effects were less pronounced with 3MMC than other 
cathinone derivatives: 
 
“Good thing is that side effects seem to be very acceptable, almost no increase in heartbeat 
whatsoever and no vasoconstriction.”  
 
Respiratory problems were reported by 13 users who experienced shortness of breath upon 
intake of 3MMC, alpha-PVP, MDPV, mephedrone and methylone. A chesty cough was 
reported by one of the users who took mephedrone. Several skin adverse effects were seen (n 
= 21) including: discolouration of skin, dryness/itchiness, allergy and rash. Discolouration of 
the knees and joints were reported by eight users who experienced yellow or brown patches. 
Nine users described bladder pain and difficulty in urination following the intake of 3MMC, 
methylone and mephedrone.  
 
Drug drug interactions 
Drug-drug interactions of cathinones were encountered with combinations of stimulants, 
depressants, stimulants/depressant mixtures, vitamins/nutrition supplements and 
hallucinogens. Stimulant mixtures induced euphoria and increased energy as desired effects 
and caused nervous system and cardiovascular toxicities (Table 3). Depressants (e.g. alcohol, 
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benzodiazepines and herbal sleep aids) were used in order to counteract the effect of 
cathinones in relation to inducing sleep and making the come down easier. Vitamins and 
nutrition supplements were used to combat various side effects such as tooth grinding. Fewer 
adverse effects were reported upon the mixing of cathinones with hallucinogen and were 
limited to psychological hallucinations.  
 
Discussion 
The study explored discussion threads regarding cathinones’ use from Internet forums. Three 
main themes emerged from the discussion threads in relation to cathinones: (1) use, (2) 
pharmacological effects and (3) toxicity.  
 
Users on discussion threads supported each other in sharing experiences and knowledge 
regarding cathinones’ use. Many users appeared to be knowledgeable regarding NPS and 
cathinones in relation to dose, duration of action, effects and toxicity. The information 
extracted from the forums contributes to the greater body of knowledge surrounding NPS 
(Corazza et al., 2014). Users related doses, frequency of intake and route of intake to the 
effectiveness of the drug. Newer routes for intake of drugs emerged which were not repeated 
in previous studies including sublingual and eyeballing. Sublingual and eyeballing routes 
were described as giving faster effects (Karila et al., 2015) but with more adverse effects. An 
interesting finding in this study was user-comments regarding the purity of the drugs and its 
implications on the effects. Previous studies have reported low and variable purity of NPS 
products (Assi et al., 2011; Assi et al., 2016; Brandt et al., 2010). Users interpreted physical 
changes of the powder (colour change and water absorption) as an indication of 
ineffectiveness. This change could be attributed to degradation of the drug.  
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Not only the general effects were reported to cathinone derivatives but also the strength of the 
effects associated with specific cathinone derivatives (such as mild, moderate or sever 
euphoria). Effects of drugs were discussed in relation to single and multi-drug intake. The 
main positive effects reported by users were increased energy, confidence, euphoria, 
increased empathy, intimacy and desire to socialise. These findings were found to be 
consistent with results from key quantitative studies in the literature that reported improved 
mood and increased socialising ability associated with the use of cathinone derivatives 
(Karila & Reynaud, 2011; Schifano et al., 2011; Spiller et al., 2011;  Winstock et al., 2011). 
Users reported that it was easier to start a conversation after taking a cathinone derivative. 
They described cathinone derivatives as a ‘social lubricants’ which is a similar characteristic 
of some classical drugs (e.g. MDMA) (Phillips et al., 2014). The socialising effect justified 
the users’ intentions behind taking cathinones despite their short duration of action and 
potential negative effects. Additional reported positive effects were desire for alertness, 
improved concentration and cognitive enhancement (Karila & Reynaud, 2011; Coppola & 
Mondola, 2012). Nonetheless, many adverse effects associated with the use of cathinones 
were reported including psychiatric, cardiovascular and neurological complications (Karila et 
al., 2015; Mas-Morey et al. 2013; Prosser & Nelson, 2012). Cardiovascular adverse effects 
included: hypertension, hyperthermia, and tachycardia. Neurological and psychotic problems 
reported were: cognitive degradation, increased anxiety, hallucinations, insomnia, paranoia, 
depression, psychosis and memory problems. Psychotic problems associated with the use of 
cathinones could be more severe than psychosis encountered with amphetamine (Borek & 
Holstege, 2012; Loeffler et al., 2012). Other effects included: appetite suppression, breathing 
difficulties, muscle tension and hyperthermia (Phillips et al., 2014). 
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The findings of the study uncovered new information in relation to the use and safety of 
cathinones which has not been described in the scientific literature. Internet discussion 
forums supported the scientific literature in providing useful information regarding the 
dangers associated with the use of NPS (Deluca et al., 2012). This information should be 
taken into account when monitoring NPS and assessing their safety.  
 
Several limitations were encountered in this study. The study could not explore the 
motivation of the users for cathinones’ over other NPS derivatives. This can be an important 
aspect in relation to drug prevention. Because of the nature of the discussion forums, it was 
not possible to access the sociodemographic data of the users. The information accessed from 
discussion forums was limited for the data available. Missing information in relation to 
dosage and frequency in some threads could influence the results. There was no method for 
verifying the subjective experience of the users regarding effects and toxicities. Nonetheless, 
this information could serve as preliminary data for further research where no other sources 
are available. The varying effects and toxicities reported among users in this study urges the 
need for further research into NPS. With limited resources in the literature, assessment of 
data obtained from emergency department admissions (alongside discussion forums) can be 
beneficial.   
 
In conclusion, the present study uncovered many information regarding the uses, effects and 
toxicity of cathinones which were lacking in the scientific literature. Users shared their 
experiences associated with single and multidrug use. Information provided via Internet 
discussion forums could be used as an early warning system for NPS.  
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Table 1 Sites that were considered in this study 
 
Website Threads found Threads excluded 
www.bluelight.org 106 17 
www.chemrus.com 10 6 
www.drugs-forum.com 47 7 
www.erowid.com 142 6 
www.legalhighsforum.com 19 5 
www.partyvibe.com 15 8 
www.reddit.com 21 8 
Total 360 57 
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Table 2 Cathinone derivatives reported by the users in discussion forums 
 
Substitution 
alkyl (n = 254) halogen (n = 153) 
methylenedioxy (n 
= 300) pyrrolidinyl (n = 115) 
• 2MMC  • 3FMC • 3,4-MDPV • alpha-PBP 
• 3MMC • 4BMC • 5ME • alpha-PHP 
• 3,4-DMMC • 4F-apha-PVP • butylone • alpha-PVP 
• 4MBP • 4FMC • ethylone • NRG-1 
• 4EMC 
 
• methylone • alpha-PHPP 
• 4MEC 
 
• pentylone 
 
• ethcathinone 
  • mephedrone 
   • methedrone 
   • mexedrone 
   • pentedrone       
 
2MMC: 2-methylmethcathinone, 3MMC: 3-methylmethcathinone, 3,4-DMMC: 3,4-dimethylmethcathinone, 4-EMC: 4-
ethylmethcathinone, 4MEC: 4-methylethcathinone, 3FMC: 3-fluoromethcathinone, 4BMC: 4-bromomethcathinone, 4F-alpha-
PVP: 4-fluoro-α-2-(1-pyrrolidinyl)-valerophenone, 4FMC: 4-fluoromethcathinone, 3,4-MDPV: 3,4-methylenedioxypyrovalerone, 
5ME: 5-methylethylone, alpha-PBP: alpha-pyrrolidinobutiophenone, alpha-PHP: alpha-pyrrolidinohexiophenone, alpha-PVP: 
alpha-pyrrolidinopentiophenone, NRG-1: naphyrone, alpha-PHpP: 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one. 
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Table 3 Drug-drug interactions reported by the users 
 
NPS 
derivative 
Drug Effect 
Stimulants mixtures 
2MMC 2MA myocarditis 
Alpha-PHP Synthetic 
cannabinoid 
intense panic/delirium 
MDPV tobacco painful urination 
MDPV cocaine tachycardia 
Mephedrone MDMA weird light- headed mini 
waves 
of energy/rush, 
overpowering 
3MMC coffee irregular heart beat 
Mephedrone coffee increased mood 
Mephedrone coffee chest and arm pain 
Mepherone cannabis memory blacked out 
Methylone 2CB 2CB lengthens methylone 
effect 
Methylone 2CE erotic thoughts 
Methylone 2CI  
Methylone MDMA overpowering 
Hallucinogen mixtures 
MDPV LSD auditory hallucinations 
MDPV magic  
mushrooms 
wandering, feeling lost 
Depressant mixtures 
3MMC alcohol increased sociability 
3MMC alcohol increased sociability 
MDPV alcohol easier come down 
MDPV phenazepam induce sleep 
MDPV etizolam beats insomnia 
Mephedrone alcohol improving experience but  
counteract is slow 
Mephedrone alcohol induce sleep 
Mephedrone alprazolam sleep aid 
Mephedrone GBL discolouration of the knees 
Mephedrone milk thistle induce sleep 
Methylone alcohol induce sleep 
Methylone aniracetam,  
piracetam 
strong palpitations 
Novel psychoactive substances mixtures 
3MMC 3FA feeling down and depressed 
3MMC methylone smooth and silk 
Alpha-PHP ethylphenidate enhanced sexual activity 
MDPV MXE auditory hallucinations 
Mephedrone methylone Stronger stimulant effect, 
panic attack 
Methylone MDAI nausea and chalky taste in 
the mouth 
Methylone MDPV very strong effects 
Methylone 2CE increased erotic thoughts 
Vitamins/supplements mixtures 
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Methylone magnesium magnesium combats tooth 
grinding 
Methylone calcium better experience 
Mephedrone multivitamins blushing, minor circulatory 
changes 
Other 
3MMC melatonin induce sleep 
MDPV diphenhydramine facilitate come down 
2MMC: 2-methylmethcathinone, 2CB: 4-bromo-2,5-dimethoxyphenethylamine, 2CE: 4-ethyl-2,5-dimethoxyphenethylamine, 
2CI: 4-iodo-2,5-dimethoxyphenethylamine, 2MA: 2-methylamphetamine,3FA: 3-fluoroamphetamine, 3MMC: 3-
methylmethcathinone, alpha-PVP: alpha-pyrrolidinopentiophenone, GBl: gamma-butyrolactone, LSD: lysergic acid 
diethylamide, MDAI: methylenedioxy-2-aminoindan, MDMA: methylenedioxymethamphetamine, MDPV: 
methylenedioxypyrovalerone, MXE: methoxetamine. 
 
